XENT · Intersect Ent, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Revenue | $106.75M | $80.55M | $109.14M | $108.47M | $96.30M | $78.71M |
| Cost of Revenue | $30.01M | $30.31M | $21.77M | $22.61M | $15.50M | $13.00M |
| Gross Profit | $76.74M | $50.25M | $87.37M | $85.86M | $80.80M | $65.70M |
| R&D | $27.94M | $19.35M | $24.28M | $19.26M | $18.36M | $18.89M |
| SG&A | $122.07M | $98.55M | $108.48M | $91.60M | $80.05M | $72.93M |
| Total Operating Expenses | $217.78M | $117.90M | $132.76M | $110.86M | $98.41M | $91.82M |
| D&A | $4.81M | $2.84M | $2.67M | $1.88M | $1.46M | $1.17M |
| Operating Income | ($141.04M) | ($67.65M) | ($45.39M) | ($25.01M) | ($17.60M) | ($26.11M) |
| Interest Expense | $6.44M | $2.75M | - | - | - | - |
| Income Tax | ($1.69M) | ($416.0K) | - | $0 | $0 | $0 |
| Net Income | ($159.63M) | ($72.32M) | ($42.99M) | ($22.92M) | ($16.36M) | ($25.22M) |
| EPS - Basic | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - |
Balance Sheet
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $38.40M | $13.52M | $20.65M | $9.46M | $19.84M | $9.86M |
| Accounts Receivable | $17.33M | $14.59M | $19.11M | $19.62M | $16.59M | $14.42M |
| Inventory | $18.60M | $12.05M | $17.00M | $11.59M | $8.47M | $5.61M |
| Accounts Payable | $8.89M | $6.04M | $4.06M | $6.20M | $3.40M | $3.27M |
| Current Assets | $106.00M | $118.17M | $129.05M | $134.67M | $130.29M | $125.29M |
| Total Assets | $146.87M | $227.38M | $147.90M | $140.96M | $135.57M | $129.78M |
| Current Liabilities | $57.16M | $44.25M | $18.94M | $19.73M | $17.68M | $14.36M |
| Long-term Debt | $127.35M | - | - | - | - | - |
| Total Liabilities | $215.94M | $160.37M | $29.84M | $19.97M | $18.36M | $15.38M |
| Stockholders' Equity | ($69.07M) | $67.01M | $118.06M | $120.99M | $117.22M | $114.40M |
| Retained Earnings | ($462.71M) | ($303.07M) | ($230.76M) | ($187.76M) | ($164.84M) | ($148.48M) |
Cash Flow
| Line item | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($59.47M) | ($35.69M) | ($27.25M) | ($20.06M) | ($8.04M) | ($20.06M) |
| Investing Cash Flow | $49.18M | ($22.75M) | $18.89M | ($6.86M) | $9.25M | ($6.86M) |
| Financing Cash Flow | $36.59M | $68.74M | $19.55M | $1.97M | $8.77M | $1.97M |
| CapEx | $2.02M | $873.0K | $3.73M | $2.12M | $2.28M | $2.07M |
| Free Cash Flow | ($61.49M) | ($36.57M) | ($30.98M) | ($22.18M) | ($10.32M) | ($22.13M) |
Ratios
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 71.9% | 62.4% | 80.1% | 79.2% | 83.9% | 83.5% |
| Operating margin | -132.1% | -84.0% | -41.6% | -23.1% | -18.3% | -33.2% |
| EBITDA margin | -127.6% | -80.5% | -39.1% | -21.3% | -16.8% | -31.7% |
| Net margin | -149.5% | -89.8% | -39.4% | -21.1% | -17.0% | -32.0% |
| Free cash flow margin | -57.6% | -45.4% | -28.4% | -20.4% | -10.7% | -28.1% |
| FCF / Net income | 0.39 | 0.51 | 0.72 | 0.97 | 0.63 | 0.88 |
| R&D / Revenue | 26.2% | 24.0% | 22.2% | 17.8% | 19.1% | 24.0% |
| SG&A / Revenue | 114.4% | 122.3% | 99.4% | 84.4% | 83.1% | 92.7% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -108.7% | -31.8% | -29.1% | -16.3% | -12.1% | -19.4% |
| Return on equity | 231.1% | -107.9% | -36.4% | -18.9% | -14.0% | -22.0% |
| Return on invested capital | -191.2% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 1.85 | 2.67 | 6.82 | 6.82 | 7.37 | 8.72 |
| Quick ratio | 1.53 | 2.40 | 5.92 | 6.24 | 6.89 | 8.33 |
| Cash ratio | 0.67 | 0.31 | 1.09 | 0.48 | 1.12 | 0.69 |
| Leverage | ||||||
| Debt / Equity | -1.84 | - | - | - | - | - |
| Debt / Assets | 0.87 | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -21.9x | -24.6x | - | - | - | - |
| Equity multiplier | -2.13 | 3.39 | 1.25 | 1.17 | 1.16 | 1.13 |
| Liabilities / Assets | 1.47 | 0.71 | 0.20 | 0.14 | 0.14 | 0.12 |
| Efficiency | ||||||
| Asset turnover | 0.73 | 0.35 | 0.74 | 0.77 | 0.71 | 0.61 |
| Inventory turnover | 1.61 | 2.51 | 1.28 | 1.95 | 1.83 | 2.32 |
| Days sales outstanding | 59d | 66d | 64d | 66d | 63d | 67d |
| Days inventory outstanding | 226d | 145d | 285d | 187d | 200d | 158d |
| Days payable outstanding | 108d | 73d | 68d | 100d | 80d | 92d |
| Cash conversion cycle | 177d | 139d | 281d | 153d | 182d | 133d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 32.5% | -26.2% | 0.6% | 12.6% | 22.4% | 27.8% |
| Revenue CAGR (3y) | -0.5% | -5.8% | 11.5% | 20.8% | 154.2% | - |
| Revenue CAGR (5y) | 6.3% | 5.5% | 79.5% | - | - | - |
| Gross profit growth (YoY) | 52.7% | -42.5% | 1.8% | 6.3% | 23.0% | 33.3% |
| Operating income growth (YoY) | -108.5% | -49.0% | -81.5% | -42.1% | 32.6% | 3.1% |
| Net income growth (YoY) | -120.7% | -68.2% | -87.6% | -40.1% | 35.1% | 5.3% |
| EPS growth (YoY) | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -68.2% | -18.0% | -39.7% | -114.8% | 53.4% | -2.4% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -43.2% | -2.4% | 3.2% | 2.5% | -12.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$106.75M totalPropel Family Of Products$91.12M · 85.4%
Sinuva$9.07M · 8.5%
Ven Sure CUBEAnd Accessories$6.56M · 6.1%
Stability scores
Altman Z′
FY 2021 · bankruptcy risk
-4.82
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2021 · 9-point quality
3/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Intersect ENT against the 5 most active filers in the same SIC group.